60 Use of the Combined Positive Score (CPS) with the companion diagnostic PD-L1 IHC 22C3 pharmDx provides precise evaluation of PD-L1 expression across multiple tumor indications and cutoffs

60 Use of the Combined Positive Score (CPS) with the companion diagnostic PD-L1 IHC 22C3 pharmDx provides precise evaluation of PD-L1 expression across multiple tumor indications and cutoffs

Bibliographic Details
Main Authors:	Jay Milo, Stephanie Hund, Angeliki Apostolaki, Siena Tabuena-Frolli, Karina Kulangara, Francisco Ponce, Lindsay Peltz, Chris La Placa, Monika Vilardo, Brittany Watts, Grant Toland, Alex Posch
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

3 External reproducibility of PD-L1 IHC 22C3 pharmDx for colorectal carcinoma specimens at CPS ≥ 1 cutoff
by: Siena Tabuena-Frolli, et al.
Published: (2023-11-01)

50 External inter-laboratory reproducibility of PD-L1 IHC 22C3 pharmDx (SK006) for biliary tract adenocarcinoma at CPS ≥ 1 and CPS ≥ 10
by: Siena Tabuena-Frolli, et al.
Published: (2023-11-01)

Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
by: Gilad Vainer, et al.
Published: (2023-01-01)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
by: Michael Crager, et al.
Published: (2022-11-01)

81 Inclusion of PD-L1-expressing tumor cells in the combined positive score algorithm yields superior identification of positive specimens around diagnostic cut-offs across multiple indications
by: Jonathan Juco, et al.
Published: (2020-11-01)

Potential impact of HercepTest™ mAb PharmDx (Dako Omnis) (ge001) in breast cancer diagnosis
by: Andrzej Marszałek, et al.
Published: (2023-07-01)

Combined positive score (CPS) for scoring PD-L1 positivity
by: Chinmoy K Bose, et al.
Published: (2022-01-01)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
by: Xia Xiao, et al.
Published: (2021-01-01)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
by: Yu-Feng Zhou, et al.
Published: (2020-03-01)

PK-PD Integration Modeling and Cutoff Value of Florfenicol against Streptococcus suis in Pigs
by: Zhixin Lei, et al.
Published: (2018-01-01)

Optimal regimens based on PK/PD cutoff evaluation of ceftiofur against Actinobacillus pleuropneumoniae in swine
by: Da Sun, et al.
Published: (2020-09-01)

Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin Against Streptococcus suis in Piglets
by: Rui-Ling Wang, et al.
Published: (2022-07-01)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
by: Didi Feldman, et al.
Published: (2023-10-01)

Comparison of PK/PD Targets and Cutoff Values for Danofloxacin Against Pasteurella multocida and Haemophilus parasuis in Piglets
by: Yu-Feng Zhou, et al.
Published: (2022-02-01)

36 Digital Whole Slide Image (WSI) scoring is equivalent to microscope glass slide scoring for evaluation of programmed death-ligand 1 (PD-L1) expression across multiple tumor indications
by: Jay Milo, et al.
Published: (2021-11-01)

PharmXplorer
by: Klaus Schweiger, et al.
Published: (2011-02-01)

Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers
by: Shu-Fen Mo, et al.
Published: (2023-05-01)

Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis
by: Tong Xie, et al.
Published: (2021-09-01)

65 PD-L1 by RNA next generation sequencing: comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer
by: Sarabjot Pabla, et al.
Published: (2020-11-01)

Improved PHARM for JPEG Steganalysis: Making PHARM More Efficient and Effective
by: Chao Xia, et al.
Published: (2019-01-01)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
by: Jeffrey S Ross, et al.
Published: (2022-10-01)

Interpretation According to Clone-Specific PD-L1 Cutoffs Reveals Better Concordance in Muscle-Invasive Urothelial Carcinoma
by: Tzu-Hao Huang, et al.
Published: (2021-03-01)

Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy.
by: Magdalena Zajac, et al.
Published: (2020-01-01)

Beyond the PharmD
by: Yen Dang, et al.
Published: (2023-08-01)

1308 Artificial intelligence (AI)-powered immune phenotyping based on programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) in triple negative breast cancer (TNBC)
by: Chan-Young Ock, et al.
Published: (2023-11-01)

Gradient material Pd-PdHx
by: M. V. Goltsova, et al.
Published: (2018-10-01)

Die Rechercheplattform PubPharm
by: Draheim, Christina, et al.
Published: (2019-12-01)

PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience
by: Sarah Nasr, et al.
Published: (2023-09-01)

Replacing CPS
by: Michael Wald
Published: (2022-07-01)

Correction to Improved PHARM for JPEG Steganalysis: Making PHARM More Efficient and Effective [2019 50330-50346]
by: Chao Xia, et al.
Published: (2019-01-01)

PD‐L1 expression by different scoring methods and different cutoff values and correlation with clinicopathological characteristics in gastric cancer: A retrospective study
by: Lixiang Si, et al.
Published: (2023-03-01)

Pharm Care Esp en 2022
by: Ana Dago
Published: (2023-02-01)

Pharm Care Esp en 2022
by: Ana Dago
Published: (2023-02-01)

PubPharm - Der Fachinformationsdienst Pharmazie
by: Kristof Keßler, et al.
Published: (2016-09-01)

Indian Pharm.D: Should it be pursued?
by: Akram Ahmad, et al.
Published: (2014-01-01)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
by: Yiru Long, et al.
Published: (2022-05-01)

نقش PD-1/ PD-L1 و Anti-PD-1/ PD-L1 در پیشرفت و سرکوب سرطان
by: نرگس عبدالهی, et al.
Published: (2023-11-01)

Foundations of Infrastructure CPS
by: Annaswamy, Anuradha, et al.
Published: (2015)

VisualDx
by: Caitlin Carter, et al.
Published: (2014-07-01)

The Evolution of Pd
by: Sather, Aaron C., et al.
Published: (2018)